<unk> s, or SMIPs for short, are artificial proteins that are intended for use as pharmaceutical drugs. They are largely built from parts of antibodies (immunoglobulins), and like them have a binding site for antigens that could be used for monoclonal antibody therapy. SMIPs have similar biological half-life and, being smaller than antibodies, are reasoned to have better tissue penetration properties. They were invented by Trubion and are now being developed by Emergent BioSolutions, which acquired Trubion in 2010.
Small modular immunopharmaceutical
Small molecule drug conjugate
Pharmacological chaperone
Monoclonal antibody
Immunoconjugate
Generic drug
Prototype drug
Designer drug